Letter of Authorization: SARS-CoV-2 Assay (Nationwide Children’s Hospital) | NLM

Disaster Information Management Research Center | NLM

Letter of Authorization: SARS-CoV-2 Assay (Nationwide Children’s Hospital)

04/27/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 4/27/2020. This one-page letter authorizes the emergency use of the Nationwide Children's Hospital SARS-CoV-2 Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)